Wyeth Receives Approvable Letter from FDA for PRISTIQ for the Treatment of Vasomotor Symptoms Associated with Menopause (The San Francisco Examiner)
COLLEGEVILLE, Pa. ( Map ) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), announced today that it received an approvable letter from the U.S. Food and Drug Administration (FDA) for PRISTIQ(TM) (desvenlafaxine), a serotonin-norepinephrine reuptake inhibitor (SNRI), currently under review as a treatment for moderate-to-severe vasomotor symptoms (hot flashes and night sweats) associated ...

Wyeth Receives Approvable Letter From FDA for PRISTIQ for the Treatment of Vasomotor Symptoms Associated With Menopause (PRWeb via Yahoo! News)
Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that it received an approvable letter from the U.S. Food and Drug Administration (FDA) for PRISTIQ (desvenlafaxine), a serotonin-norepinephrine reuptake inhibitor (SNRI), currently under review as a treatment for moderate-to-severe vasomotor symptoms (hot flashes and night sweats) associated with menopause.